Melanoma

>

Latest News

Neoadjuvant Nivolumab Plus Ipilimumab May Define ‘New Standard of Care’ for Stage III Melanoma
Neoadjuvant Nivolumab Plus Ipilimumab May Define ‘New Standard of Care’ for Stage III Melanoma

June 2nd 2024

The combination given before lymph node dissection and response-driven adjuvant therapy reduced the risk for recurrence, progression, or death in stage III melanoma.

Adjuvant Dabrafenib/Trametinib Maintains Long-Term Survival Benefit in Stage III Melanoma
Adjuvant Dabrafenib/Trametinib Maintains Long-Term Survival Benefit in Stage III Melanoma

June 1st 2024

Adjuvant Vaccine Combo May Prolong Survival in Melanoma
Adjuvant Vaccine Combo May Prolong Survival in Melanoma

May 20th 2024

BLA for Subcutaneous Nivolumab Accepted by the FDA for Advanced/Metastatic Solid Tumors
BLA for Subcutaneous Nivolumab Accepted by the FDA for Advanced/Metastatic Solid Tumors

May 18th 2024

Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma
Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma

April 19th 2024

Latest CME Events & Activities

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

More News

© 2024 MJH Life Sciences

All rights reserved.